95% ethanol rinse combined with lauromacrogol injection versus lauromacrogol injection alone for ultrasound-guided percutaneous sclerotherapy of simple renal cysts in elderly patients: Which is safer and more effective? Authors: Kan Gao, Feiliang Wang, Lengnan Xu, Weide Dai Published: 2026 ABSTRACT AbstractObjectiveTo compare the efficacy and safety of 95% ethanol rinse combined with lauromacrogol injection versus lauromacrogol injection alone in sclerotherapy for simple renal cysts in elderly patients.MethodsThis retrospective analysis included 94 patients (63 males, 31 females; mean age, 70.15 years) with symptomatic simple renal cysts who underwent ultrasound-guided percutaneous sclerotherapy between 2019 and 2025. Forty-eight patients received lauromacrogol injection alone, while 46 patients received 95% ethanol rinse combined with lauromacrogol injection. All patients were followed up at 1, 6, and 12 months after the procedure.ResultsThe volume of simple renal cysts decreased during follow-up, from a mean initial volume of 113.2 mL to a final volume of 0.30 mL. At 12 months, the total resolution rate was 98.9% (93/94), and the cure rate was 97.9% (92/94). No significant differences were observed between the two groups in volume reduction rate, resolution rate, or cure rate during follow-up (all P > 0.05). The adverse event rate was significantly higher in the ethanol-combination group than in the lauromacrogol-monotherapy group (56.5% [26/46] vs. 29.2% [14/48]; P < 0.05). Ethanol use was associated with significantly more pain and a higher incidence of fever, even when limited to rinsing the cyst lumen prior to lauromacrogol injection.ConclusionPercutaneous sclerotherapy was successful in both groups of elderly patients with simple renal cysts. Lauromacrogol injection alone was associated with a significantly lower incidence of minor adverse events.Clinical trial numberNot applicable.Keywords: Simple renal cyst, 95% ethanol, Lauromacrogol, Sclerotherapy, Ultrasound Background Cystic renal masses represent a wide range of diseases characterized by single or multiple fluid-filled cysts in the kidney. Given their high prevalence in the general population, these lesions are frequently detected incidentally on various imaging modalities. Previous studies have demonstrated that both the number and size of cystic masses increase with age [1]. The Bosniak classification system for cystic renal masses, first introduced in 1986, has been widely adopted to stratify malignancy risk [2]. The Bosniak IIF category was incorporated in 1997, and the classification was further updated in 2019 to address identified limitations [3, 4]. According to the 2019 Bosniak classification, category I and II cysts are characterized by thin walls (≤ 2 mm) with or without a few thin enhancing septa (1–3). Category IIF cysts exhibit minimal thickening (3 mm) of one or more enhancing septa, or contain numerous (≥ 4) thin (≤ 2 mm) enhancing septa. Category III cysts are defined by one or more thick (≥ 4 mm) enhancing or irregular enhancing walls or septa, while category IV cysts are distinguished by the presence of one or more enhancing nodules [4]. Bosniak I and II cysts are classified as simple renal cysts (SRCs) and do not require follow-up unless symptoms develop or intervention is indicated. Other renal cystic masses should be monitored or referred to urology for further evaluation [4]. Large simple renal cysts (SRCs) greater than 5 cm in diameter may cause flank or back pain, hematuria, hypertension, and pelvicalyceal obstruction, depending on their specific location [5]. Ultrasound-guided sclerotherapy, a widely used minimally invasive treatment, has recently been validated as an effective and safe therapeutic option for symptomatic renal cysts, particularly in elderly patients who are at increased risk from anesthesia-related complications [6, 7]. Ethanol is the sclerosing agent most commonly administered at various concentrations [8–10]. At high concentrations, ethanol can destroy epithelial cells in the cyst wall within minutes [10, 11], but adverse events (AEs) such as drunkenness (a feeling of intoxication), moderate pain during the procedure, and mild fever within several days post-procedure occur more frequently [12]. Lauromacrogol, initially used as a local anesthetic and later adopted as a painless sclerosant in various clinical settings, has been reported to have a low incidence of allergic reactions [13, 14]. Although several clinical studies have investigated SRC treatment in adults [10, 12], few have directly compared combination therapy (ethanol rinse plus lauromacrogol injection) with lauromacrogol monotherapy in a single trial involving elderly patients. The present study compares the efficacy and safety of 95% ethanol rinse combined with lauromacrogol injection versus lauromacrogol injection alone in ultrasound-guided percutaneous sclerotherapy for elderly patients with SRCs. Materials and methods The study was conducted in the Interventional Treatment Room of the Department of Ultrasound, Beijing Hospital. Between March 2019 and April 2025, a total of 127 elderly patients with 134 SRCs who underwent ultrasound-guided percutaneous sclerotherapy were consecutively enrolled and scheduled for a 12-month follow-up. According to predefined exclusion rules, 15 patients with multiple eligible cysts, 16 patients who received lauromacrogol foam sclerotherapy, and 9 patients lost to follow-up were excluded from the final analysis (Fig. 1). Ultimately, 94 patients were included in this retrospective cohort. CONSORT-style flowchart. It demonstrates the renal cysts included in and excluded from the study Patients selection criteria Patients were selected according to the following criteria: (1) aged ≥ 60 years; (2) ultrasonographically confirmed SRC with a maximum diameter > 50 mm; (3) symptoms induced by renal cysts, such as pain, intracystic haemorrhage, infection, or hydronephrosis. The exclusion criteria were as follows: (1) allergy to ethanol or lauromacrogol; (2) pregnancy; (3) patients with serious cardiovascular or cerebrovascular diseases, severe mental disorders, or contraindications to the procedure; (4) current use of anticoagulants (within the past 2 weeks), severe coagulopathy, or bleeding diathesis; (5) active systemic infection (e.g., fever) or current use of cephalosporins; and (6) ADPKD-related renal cysts. Procedure Preoperative renal ultrasonography was performed to characterize target cyst morphology and determine the optimal puncture route. All ultrasound-guided sclerotherapy procedures were completed in an outpatient setting. Interventions were undertaken by two radiologists with over 10 years of experience in interventionl ultrasound, using two ultrasound systems: RS 80 A (Samsung, Korea) and Aplio 500 TUS-A500 (Canon Medical Systems, Japan), both equipped with a L3-5 curved-array probe. Patients were placed in the supine or lateral decubitus position under local anesthesia with 3% lidocaine. Under real‑time ultrasound guidance, a 20-gauge puncture needle was inserted into the cyst and connected to a T-junction, connecting tube, and 60-mL plastic syringe. Ten milliliters of cyst fluid was aspirated for the protein coagulation test; a positive result excluded pelvicalyceal communication, allowing complete cyst fluid drainage. When pelvicalyceal communication could not be ruled out via fluid testing, contrast‑enhanced ultrasound or contrast‑enhanced abdominal CT was arranged for confirmation. After that, in the ethanol-combination group, 95% ethanol equivalent to 20% of cyst volume (maximum 20 mL) was instilled, the lumen of the cyst was rinsed, and the mixture was reaspirated. The ethanol rinsing process was repeated three to five times, with a retention time of approximately 5 min. Subsequently, 1% lauromacrogol (lauromacrogol injection, 10 mL:100 mg; Tianyu Pharmaceutical Co. Ltd., Shanxi, China) was injected and retained within the target cyst. In the lauromacrogol-monotherapy group, only lauromacrogol was administered and retained, with a dosage equivalent to 30% of cyst volume (maximum 60 mL). After the procedure, patients were asked to apply pressure over the puncture site for 20 min and to change body positions repeatedly to ensure full contact between the sclerosant and the cyst wall. Discharge was permitted after ultrasound confirmed no active regional bleeding. Treatment allocation Owing to the non-randomized nature, group assignment was determined by the treatment time period and the evolving institutional practice during that period. All procedures and follow-up evaluations were performed by the same two experienced interventional radiologists, who used standardized techniques to minimize inter-operator bias. Follow-up Telephone follow-up was conducted to document AEs occurring within 3 postoperative days. Scheduled outpatient ultrasound reassessments were arranged at 1, 6, and 12 months after intervention. The volume of the target cyst was measured by ultrasound at baseline and each follow-up time point. Cyst volumes and volume reduction rate (VRR) were calculated using the following formulae: where a is the largest cyst diameter; b and c are the remaining mutually perpendicular diameters; Definitions Simple renal cysts (SRCs) were defined as cystic masses categorized as Bosniak I and II. Ultrasonographic features, including cyst wall and septal thickness, number of septa, and vascularity, were systematically evaluated. Cysts with wall thickness < 2 mm and absent septa were classified as Bosniak I. Those with mildly thickened walls or a few thin septa (with or without Doppler vascularity, confirmed by contrast-enhanced abdominal CT) were categorized as Bosniak II. All evaluations were independently performed by two experienced sonographers to ensure diagnostic consistency and accuracy. Success was defined as either cured (VRR greater than 90%), or effective (VRR 50‒90%). Failure was defined as a less than 50% reduction in cyst volume [7, 12]. Recurrence was defined as an increase in cyst volume of more than 25% from the lowest value observed during follow-up. Procedure-related AEs included intraoperative pain and minor hematuria; drug-related adverse drug reactions (ADRs) comprised postoperative fever and ethanol-induced drunkenness. Vertigo, vomiting, and drowsiness were classified as symptoms of moderate drunkenness [15]. Mild AEs refer to mild symptoms requiring only clinical observation without targeted medical intervention [16]. No serious AEs were observed in this cohort study. Statistical analysis Propensity scores were estimated using logistic regression, with treatment group as the dependent variable and baseline covariates (age, gender, baseline cyst volume, and lesion location) as independent variables. Covariate balance after weighting was evaluated using standardized mean differences (SMDs), with an SMD <0.10 indicating acceptable balance. Stabilized inverse probability of treatment weighting (IPTW) was applied to address baseline imbalances between the ethanol-combination group and the lauromacrogol-monotherapy group. Between‑group continuous variables with normal distribution were compared using independent‑samples Student’s t‑test; non‑parametric variables were analysed using the Mann–Whitney U test. Intra‑group longitudinal changes were assessed with the Wilcoxon signed‑rank test or Friedman test. Categorical variables were compared using chi-square tests. IPTW logistic regression was employed for binary outcomes, and IPTW mixed-effects models for repeated-measures were used for longitudinal outcomes, including fixed effects for group, time, and the group × time interaction. All analyses were conducted using R Core Team (2025). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Sample size calculation was based on pilot data: anticipated AE rates were 40% for the ethanol-combination group versus 15% for the lauromacrogol-monotherapy group. A sample size of 47 cysts per group provides 80% statistical power to detect this difference at a two-sided α of 0.05. More than 60 cysts per group were included to account for potential loss to follow-up. Results Initially, 127 elderly patients with 134 SRCs received ultrasound‑guided sclerotherapy from March 2019 to April 2025; after predefined exclusions, 94 SRCs were ultimately enrolled for final analysis (Fig. 1). Hydronephrosis was identified in 5 patients (5.3%). Patient age ranged from 60 to 92 years with a mean value of 70.15 years. Of all cysts, 49 (52.1%) cysts were in the right kidney and 45 (47.9%) cysts in the left kidney. The initial cyst volume was 113.20mL, ranging from 41.10 to 600.20 mL, with 8 cysts (8.51%) exceeding 300 mL in volume. Forty-six cysts were assigned to the ethanol-combination group (95% ethanol rinse followed by lauromacrogol injection), and the remaining 48 were assigned to the lauromacrogol-monotherapy group. Baseline demographic and cyst characteristics are presented in Table 1, with no statistically significant intergroup differences noted for all baseline variables. Cytologic testing excluded malignant cells across all aspirated cyst fluid samples. Table 1IPTW-adjusted baseline characteristics of patients in the ethanol-combination group and the lauromacrogol-monotherapy groupCharacteristicsEthanol-combinationgroupLauromacrogol-monotherapy groupWeighted PSMDNo. of patients4648Effective sample size42.343.9Age, years70.02 ± 6.6970.14 ± 7.080.936-0.017Baseline volume (mL)105.32 (43.27–600.20)120.90 (41.10-377.18)0.7390.069Baseline volume category: <300 mL40 (87.0%); IPTW 91.2%46 (95.8%); IPTW 93.2%0.713Baseline volume category: >300 mL6 (13.0%); IPTW 8.8%2 (4.2%); IPTW 6.8%0.076Gender: Male30 (65.2%); IPTW 66.4%33 (68.8%); IPTW 67.5%0.913-0.023Gender: Female16 (34.8%); IPTW 33.6%15 (31.2%); IPTW 32.5%Location1: Right19 (41.3%); IPTW 51.4%30 (62.5%); IPTW 51.1%0.9750.006Location1: Left27 (58.7%); IPTW 48.6%18 (37.5%); IPTW 48.9%Location2: Upper18 (39.1%); IPTW 39.1%18 (37.5%); IPTW 38.5%0.9740.043Location2: Middle18 (39.1%); IPTW 23.5%12 (25.0%); IPTW 22.0%Location2: Lower18 (39.1%); IPTW 37.4%18 (37.5%); IPTW 39.5%Note: IPTW preserved all original cases. Effective sample size (ESS) after stabilized IPTW is reported. Continuous variables are presented as weighted mean ± SD and weighted median (observed range). Categorical variables are presented as weighted proportions. SMD represents the maximum absolute level‑specific standardized mean difference IPTW-adjusted baseline characteristics of patients in the ethanol-combination group and the lauromacrogol-monotherapy group Note: IPTW preserved all original cases. Effective sample size (ESS) after stabilized IPTW is reported. Continuous variables are presented as weighted mean ± SD and weighted median (observed range). Categorical variables are presented as weighted proportions. SMD represents the maximum absolute level‑specific standardized mean difference Binary logistic regression demonstrated that treatment regimen was independently associated with the occurrence of AEs (P < 0.05; Table 2), whereas age, sex, initial cyst volume, and cyst location exerted no significant influence on AE incidence (P > 0.05; Table 2). All patients in the lauromacrogol-monotherapy group attained successful treatment response (100% cure rate), precluding convergence of logistic regression analysis of efficacy endpoints. Table 2Results of IPTW-adjusted logistic regression analysis for adverse event (AE)CharacteristicsNo.AE n (%)Univariate OR (95% CI) P Multivariable OR (95% CI) P Total AE9440 (42.6%)Age, per year0.992 (0.931–1.056)0.7990.992 (0.925–1.065)0.831Baseline volume, per mL1.000 (0.996–1.005)0.9541.000 (0.996–1.005)0.924Gender, male / female63/3125/15 (39.7%/48.4%)0.790 (0.321–1.941)0.6070.769 (0.297–1.996)0.590Location, left / right45/4917/23 (34.7%/51.1%)1.510 (0.638–3.573)0.3481.552 (0.645–3.734)0.327Treatment, ethanol-combination group / lauromacrogol-monotherapy group46/4826/14 (56.5%/29.2%)2.871 (1.189–6.933)0.0192.909 (1.193–7.090)0.019Note: AE refers to the occurrence of at least one adverse event. ORs were estimated using IPTW-adjusted logistic regression. A two-sided P value < 0.05 was considered statistically significant Results of IPTW-adjusted logistic regression analysis for adverse event (AE) Note: AE refers to the occurrence of at least one adverse event. ORs were estimated using IPTW-adjusted logistic regression. A two-sided P value < 0.05 was considered statistically significant All included cysts completed a minimum 12 months follow-up, with significant cyst shrinkage observed in both groups after sclerotherapy. Serial cyst volume changes and corresponding volume reduction rates (VRRs) are summarized in Table 3. At the 12-month follow-up, 93 of the 94 cysts (98.9%) achieved efficient treatment outcome (VRR > 50%), and 92 cysts (97.9%) reached cure criteria (VRR > 90%) (Fig. 2). No significant differences in the resolution rate or cure rate were observed between the ethanol-combination and the lauromacrogol-monotherapy groups, as shown in Table 3. One failure case involved a cyst located at the upper pole of the kidney with VRR < 50% at the 12-month assessment (Fig. 3). Hydronephrosis in 5 cases were completely resolved (2 from ethanol-combination group, 3 from lauromacrogol-monotherapy group), and no cyst recurrence was detected in either cohort by the 12-month endpoint. Table 3Results of IPTW-adjusted repeated-measures mixed-effects model for treatment outcomesOutcomeGroup / effectBaseline1 month6 months12 monthsMD (95% CI)F P Volume (mL)Ethanol-combinationgroup105.32 (43.27–600.20)13.80(1.33-200.19)1.31(0.00-67.70)0.25(0.00-71.93)Volume (mL)Lauromacrogol-monotherapy group120.90 (41.10-377.18)17.14(0.40-128.69)1.49(0.00-20.89)0.30(0.00-12.90)Volume (mL)Group effect8.234(-5.947,22.415)2.3120.132Volume (mL)Time effect148.053< 0.001Volume (mL)Group x time effect0.0360.991VRR (%)Ethanol-combinationgroup85.88(27.84–96.93)98.97 (17.29–100.00)99.69 (12.12–100.00)VRR (%)Lauromacrogol-monotherapy group85.59(49.73–99.20)98.56 (87.21–100.00)99.40 (91.99–100.00)VRR (%)Group effect-2.846(-6.940, 1.248)1.8010.183VRR (%)Time effect120.479< 0.001VRR (%)Group x time effect0.6540.521Note: Descriptive statistics are presented as weighted medians with observed ranges. F and P values are derived from repeated-measures mixed-effects models. The mean difference (MD) and 95% confidence interval (CI) represent the model-estimated average group difference (Ethanol-combination group vs. Lauromacrogol-monotherapy group). The model incorporates fixed effects for group, time, and the group-by-time interaction, as well as a random intercept for each patient Results of IPTW-adjusted repeated-measures mixed-effects model for treatment outcomes Ethanol-combination group 13.80 (1.33-200.19) 1.31 (0.00-67.70) 0.25 (0.00-71.93) Lauromacrogol -monotherapy group 17.14 (0.40-128.69) 1.49 (0.00-20.89) 0.30 (0.00-12.90) 8.234 (-5.947,22.415) Ethanol-combination group 85.88 (27.84–96.93) Lauromacrogol -monotherapy group 85.59 (49.73–99.20) -2.846 (-6.940, 1.248) Note: Descriptive statistics are presented as weighted medians with observed ranges. F and P values are derived from repeated-measures mixed-effects models. The mean difference (MD) and 95% confidence interval (CI) represent the model-estimated average group difference (Ethanol-combination group vs. Lauromacrogol-monotherapy group). The model incorporates fixed effects for group, time, and the group-by-time interaction, as well as a random intercept for each patient Ultrasound images from a successful case of 67-year-old female with a single renal cyst. a, Prior to treatment, the cyst measured 7.0 cm × 6.8 cm in the lower pole of the left kidney, with a volume of 132 mL. b, At 1 month post-treatment, the cyst showed marked reduction. c, At 6 months post-treatment, the cyst continued to diminish. d, At 12 months, the cyst had decreased substantially, and the cyst cavity had disappeared, yielding a volume reduction rate (VRR) of 100% Ultrasound images from an unsuccessful case of a 65-year-old male with a single renal cyst. a, Prior to treatment, the cyst measured 6.6 cm × 6.5 cm in the upper pole of the left kidney, with a volume of 110.01 mL. b, At 1 month post-treatment, only mild reduction was observed. c, At 6 months post-treatment, the cyst showed no significant change. d, At 12 months, the cyst exhibited partial reduction, measuring 5.7 cm × 4.2 cm with a volume of 58.88 mL, resulting in a volume reduction rate (VRR) was 46.68% In total, 40 adverse events were documented among the 94 study subjects (Table 4). Ethanol-related adverse drug reactions (ADRs) including vertigo, vomiting, and drowsiness consistent with moderate drunkenness, were detected in the ethanol-combination group. The most prevalent AEs overall were procedural pain and transient fever secondary to sclerosants absorption; minor intracystic haemorrhage constituted another rare transient adverse finding. The overall AE rate differed significantly between the ethanol-combination group (56.5%) and lauromacrogol-monotherapy group (29.2%). Despite ethanol being used solely for pre‑injection cyst rinse in the combined regimen, ethanol exposure contributed to procedural pain, post‑procedural fever and drunkenness. All AEs resolved spontaneously within one week in all patients, without additional pharmacological or invasive intervention. Table 4Results of IPTW-adjusted comparison of adverse events (AEs) between the ethanol-combination group and the lauromacrogol-monotherapy groupAEEthanol-combinationgroupLauromacrogol-monotherapy groupIPTW OR (95% CI) P Total AE26 (56.5%); IPTW 52.1%14 (29.2%); IPTW 27.5%2.871 (1.189–6.933)0.019Pain13 (28.3%); IPTW 26.4%9 (18.8%); IPTW 18.0%1.634 (0.601–4.439)0.336Fever11 (23.9%); IPTW 21.6%4 (8.3%); IPTW 7.6%3.340 (0.950-11.745)0.060Drunkenness2 (4.3%); IPTW 4.1%0 (0.0%); IPTW 0.0%5.119 (0.389–717.150)0.232Intracystic haemorrhage0 (0.0%); IPTW 0.0%1 (2.1%); IPTW 1.8%0.370 (0.002–7.838)0.526Note: Each cell reports the original number (n) and percentage (%), along with the IPTW-adjusted percentage Results of IPTW-adjusted comparison of adverse events (AEs) between the ethanol-combination group and the lauromacrogol-monotherapy group Note: Each cell reports the original number (n) and percentage (%), along with the IPTW-adjusted percentage Discussion Simple renal cysts (SRCs) are commonly identified incidentally during routine ultrasonographic health screening, with prevalence increasing progressively with age¹. Reported rates range from 10% to 30% in adults and up to nearly 40% in individuals aged ≥ 70 years. Clinical presentations vary depending on cyst etiology, anatomic location, and morphological features. For most small SRCs without significant clinical symptoms, follow-up alone is sufficient. Large peripelvic or parapelvic cysts may obstruct the collecting system and lead to hydronephrosis, while elderly patients with large cysts may present with flank pain or intracystic haemorrhage following abdominal trauma [5, 17]. Active intervention is warranted once these clinically significant complications emerge [18]. Currently, surgery is not recommended as the first-line option for elderly patients due to its high risk and potential for severe complications. In contrast, percutaneous sclerotherapy has evolved into a minimally invasive and effective treatment modality, associated with low recurrence rates for cystic lesions in various organs, including symptomatic SRCs and cysts associated with autosomal dominant polycystic kidney disease (ADPKD) [6–8, 19]. A variety of sclerosants are available for clinical use across different centers [6–8]. Ethanol remains widely adopted in clinical studies owing to its rapid ablative bioactivity at various concentrations [9, 10]; however, some studies have reported that ethanol is associated with a higher adverse event (AE) burden compared with lauromacrogol, a newer sclerosing agent [12, 20]. Extravasation of ethanol into pericystic soft tissue may cause mild adverse events, including pain from local tissue corrosion, transient fever, microscopic hematuria, and moderate drunkenness [7, 10]. Lauromacrogol, a surfactant sclerosing agent, exhibits strong anti-angiogenic effects both in vitro and in vivo [21], acts on damaged endothelium through its steric structure [22], and induce fibrosis in the tubular epithelium. Renal cysts are postulated to originate from diverticula of the distal and collecting tubules [23]. Accordingly, this sclerosant has been adopted for the treatment of SRCs and cystic lesions in other organs and clinical conditions, including off-label use [24]. Our previous study confirmed that ultrasound-guided percutaneous lauromacrogol injection is an effective treatment for cystic thyroid nodules [14]. As a non-ester local anesthetic, lauromacrogol is painless upon injection and carries a low risk of tissue necrosis in the event of extravasation [13]. The short‑ and long-term safety of liquid or foam-formulated lauromacrogol has been well documented in multiple studies [25, 26], with proven feasibility for ADPKD-associated renal cysts as well [19]. Consistent with prior literature, our current data demonstrate equivalent therapeutic efficacy and improved safety with standalone lauromacrogol compared with 95% ethanol rinse combined with lauromacrogol; the lauromacrogol-monotherapy group exhibited significantly lower rates of transient post-procedural fever and mild intraprocedural pain. In our study, both groups achieved favorable cure rates and low complication rates relative to historical published data, which may be attributable to several technical refinements implemented in our center. Precise needle insertion into the cyst cavity is a core determinant of procedural success. As previously reported by Yongue, upper-pole renal cysts demonstrate inferior sclerotherapy outcomes secondary to difficult access and incomplete cyst fluid evacuation [12]. We overcame this limitation by establishing modified posterior or lateral transcutaneous puncture trajectories for upper-pole lesions. This alternative approach avoids vulnerable adjacent structures including the spleen and other surrounding structures, minimizes respiratory excursion interference, and eliminates the need for rigorous breath-holding during puncture. Second, we performed complete cyst fluid aspiration and repeated saline rinse until the outflow became clear, ensuring an optimal intralesional sclerosant concentration to maximize ablative efficacy. Moreover, we adopted a slender 20-gauge rigid puncture needle (< 1 mm in diameter) instead of a larger 18-gauge needle or a pigtail drainage catheter. Although aspiration is slower with the thinner needle, it minimizes iatrogenic renal parenchymal injury. Only two cases resulted in suboptimal outcomes: one treatment failure (VRR < 50%) and one partial response (VRR: 50–90%). Apart from cyst anatomical location, operator clinical experience directly impacts final therapeutic efficacy. Early in our study, inadequate operative proficiency led to one upper-pole cyst treatment failure; later, another patient achieved only partial reduction because gas leaked into the cavity following accidental detachment of the connecting tube. Treatment failure, particularly in the ethanol-combination group, is associated with an increased risk of AEs, including procedural pain and intracystic hematuria, predominantly due to inadvertent ethanol extravasation into perilesional tissues. Large-volume SRCs treated with ethanol rinse are more prone to post-interventional fever and drunkenness. Additionally, excessive blunt abdominal trauma should be avoided postoperatively, especially among elderly patients receiving chronic preoperative anticoagulation. This study was a non-randomized, single-center, retrospective design. Several limitations should be acknowledged, including a relatively modest sample size and incomplete data collection. Procedure-related pain was not adequately assessed due to the absence of visual analogue scale (VAS) pain scores. To maintain consistency and minimize bias, we excluded cases with multiple cysts or large cysts treated with foam lauromacrogol. Consequently, our clinical experience with these excluded subgroups was limited. Additionally, factors such as sclerosant formulation and intrinsic cyst characteristics, which may influence the efficacy and safety of sclerotherapy, were not sufficiently analyzed. The 12-month follow-up period may also be inadequate to detect late recurrences. The non-randomized, retrospective design and time-dependent changes in treatment preferences introduced inherent selection bias and confounders. Therefore, our findings should be interpreted as associations rather than causal relationships. This study should be regarded as hypothesis-generating evidence to inform the design of future prospective randomized controlled trials (RCTs). We plan to conduct a series of well-designed studies to systematically address these limitations. Conclusions In this retrospective cohort study of elderly patients (≥ 60 years) with symptomatic simple renal cysts (SRCs), ultrasound-guided lauromacrogol injection alone demonstrated comparable efficacy and a significantly lower incidence of minor adverse events compared with the combination of 95% ethanol rinse and lauromacrogol injection. However, owing to the absence of quantitative pain scales, the retrospective design, potential selection bias, and the single-center setting, these findings indicate an association rather than definitive evidence of superiority. Large-scale, multicenter, prospective RCTs are warranted to validate these results and to further determine the optimal sclerotherapy regimen for elderly patients with SRCs. Acknowledgements We sincerely thank our colleagues at the Institute of Geriatric Medicine, the Departments of Nephrology, and the Department of Ultrasound at the Beijing Hospital for their assistance with this study. Researcher Zeng, Drs. Wang, Fan, and Shui contributed equally to this work. Abbreviations Simple Renal Cysts Volume Reduction Rate Autosomal Dominant Polycystic Kidney Disease Adverse Event Adverse Drug Reaction Standardized Mean Differences Inverse Probability of Treatment Weighting Visual Analogue Scale Randomized Controlled Trials Author contributions FL W and KG performed the sclerotherapy procedure, and KG was a major contributor to the manuscript. NL X and WD D reviewed and revised the manuscript. All authors have read and approved the final version of the manuscript. Funding Not applicable. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate This retrospective study was conducted in accordance with the principles of the Declaration of Helsinki. It was reviewed and approved by the Institutional Review Board of Beijing Hospital, National Center of Gerontology (a tertiary academic medical center in Beijing), with the ethical approval number 2024BJYYEC-KY038-02. Written informed consent, including permission for anonymized clinical data usage for research purposes, was obtained from all patients prior to procedural intervention. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.